|

XH001 Injection Clinical Trials

3 actively recruiting trials

▲ +1 trial since May 2026

Pipeline

Phase 1: 3

Top Sponsors

  • Shenzhen Xinhe Biomedical1
  • Jia Wei1
  • Beijing GoBroad Hospital1

Indications

  • Cancer3
  • Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)1
  • Liver Disease1
  • Advanced Gastric Cancer1
  • Gastrointestinal Cancer1

Other3 trials

Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
Phase 1
Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer
Phase 1
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.